Neuronetics Neurostar Tms System™ User Manual: Confidential

Neuronetics
NeuroStar
TMS System™
User Manual
52-40001-000 DRAFT 005a

18 December 2006
CONFIDENTIAL
Copyright ©2006 Neuronetics, Inc. All rights reserved.

NeuroStar TMS System™ User Manual 52-40001-000 DRAFT 005
Preface
This manual provides operating instructions and guidelines for the use of the Neuronetics®
NeuroStar TMS System.
Federal (U.S.A.) law restricts this device to sale by or on the order of a

physician.
User Requirements and Training

The Neuronetics NeuroStar TMS System is used by prescription only under the supervision
of a physician. The instructions in this manual assume that the user has been trained in the
proper use of the Neuronetics® NeuroStar TMS System and that he or she has the required
medical education and experience to operate the device safely and effectively. If you need
training, please contact Neuronetics.
Intended Use and Indication

The NeuroStar TMS System is indicated for the treatment of major depressive disorder.
Patent and Trademark Information

Equipment and software that comprise the NeuroStar TMS System are covered by the
following U.S patents: 6,255,815, 6,161,757, 5,725,471, 6,132,361, 6,086,525, 6,425,852,
6,491,620, with other patents pending.
Neuronetics® and MT Assist® are registered trademarks of Neuronetics, Inc.
Contact Information
Neuronetics, Inc.
One Great Valley Parkway, Suite 2
Malvern, PA 19355
Tel: 610-640-4202
Fax: 610-640-4206
Alternatively, you can send your questions to the following E-mail address:
techsupport@neuronetics.com.
The Neuronetics Web site address is http://www.neuronetics.com
To purchase supplies, accessories, or additional NeuroStar TMS Systems, call Neuronetics at

610-640-4202.
This User Manual in its entirety is protected from unauthorized photocopying by United
States copyright law.
Copyright © 2006 Neuronetics, Inc.

All rights reserved.
Neuronetics, Inc. CONFIDENTIAL iii

How to Use This Manual

• SECTION 1, INTRODUCTION, contains cautions, warnings, and important clinical
information for all users. It also provides a high-level description of the NeuroStar
TMS System itself. All users need to read and be familiar with this section.
• SECTION 2, NEUROSTAR TMS SYSTEM CONTROLS, describes and illustrates
the NeuroStar TMS System parts with which you will have regular interaction. The
terms and part names in this section are used in describing the procedures in Section
3 and Section 4. All users need to read and be familiar with this section.
• SECTION 3, DAILY TREATMENT ROOM PREPARATION, lists the steps to
ensure that the NeuroStar TMS System is ready to provide treatment and that you
have the required supplies on hand. All users need to read and be familiar with this
section.
• SECTION 4, CLINICIAN’S INSTRUCTIONS, provides detailed step-by-step
instructions for using the NeuroStar TMS System to treat patients. It covers patient
screening, treatment planning, patient positioning, motor threshold location, motor
threshold level determination, and treatment steps. All users need to read and be
familiar with this section.
• SECTION 5, SYSTEM ADMINISTRATOR INSTRUCTIONS, provides step-by-
step instructions for managing the system data. It also includes a technical
explanation of the system’s operating principles. Only system administrators and
technical personnel will need to use this section.
• SECTION 6, SYSTEM MAINTENANCE INSTRUCTIONS, provides instructions
for maintaining the system, including basic maintenance, diagnostics and
troubleshooting.
• SECTION 7, USING PDMS, provides step-by-step instructions for operating the
Practice Data Management System.
• APPENDICES contain supplemental information that is useful in operating the
system.
Neuronetics, Inc. CONFIDENTIAL iv

Table of Contents
Preface ..................................................................................................................................... iii
User Requirements and Training ............................................................................................. iii
Intended Use and Indication .................................................................................................... iii
Patent and Trademark Information .......................................................................................... iii
Contact Information................................................................................................................. iii
1. Introduction ................................................................................................................... 1-1
1.1. Technical Overview .............................................................................................. 1-2
1.2 Indications ............................................................................................................. 1-2
1.3 Contra- indications ................................................................................................. 1-3
1.4 Warnings................................................................................................................. 1-7
1.5 Clinical Precautions .............................................................................................. 1-8
1.6 Procedure Warnings and Cautions ........................................................................ 1-9
1.7 Emergency Procedures........................................................................................ 1-10
1.8 Special Patient Populations ................................................................................. 1-11
1.9 Adverse Experiences........................................................................................... 1-11
1.10 Minimal Operator Training ................................................................................. 1-13
1.11 General System Description................................................................................ 1-13
1.12 Connection to Other Equipment.......................................................................... 1-14
1.13 HIPAA Compliance ............................................................................................ 1-14
2. NeuroStar TMS System Controls.................................................................................. 2-1
2.1 NeuroStar TMS System Overview........................................................................ 2-1
2.2 Standard Configuration ......................................................................................... 2-1
2.3 Options .................................................................................................................. 2-9
2.4 Supplies ................................................................................................................. 2-9
3 Daily Treatment Room Preparation............................................................................... 3-1
3.1 Completing the Checklist...................................................................................... 3-1
3.2 Preparing the Treatment Room ............................................................................. 3-2
3.3 Attaching the SenStar™ to the Coil...................................................................... 3-2
3.4 Starting Up and Logging In .................................................................................. 3-3
4 Clinician’s Instructions.................................................................................................. 4-1
4.1 Screening Patients ................................................................................................. 4-1
4.2 Planning the Treatment Schedule.......................................................................... 4-1
4.3 Initiating a Patient ................................................................................................. 4-2
4.4 Positioning the Patient .......................................................................................... 4-4
4.5 Finding the Patient’s Motor Threshold Location ................................................ 4-14
4.6 Determining the Patient’s MT Level................................................................... 4-23
4.7 Initiating a Treatment Session............................................................................. 4-30
4.8 Treating Patients ................................................................................................. 4-31
5 System Administrator Instructions ................................................................................ 5-1
5.1 Changing System Configuration 5-2
5.2 Performing Diagnostic Functions ......................................................................... 5-13
5.10 Understanding the Technical Design.................................................................... 5-26
5.10.1 Principles of Operation ......................................................................................... 5-24
5.10.2 Main Technical Specifications ............................................................................. 5-29
6 Maintaining the System .................................................................................................. 6-1

7 Using the Practice Data Management System (PDMS) .................................................. 7-1
Neuronetics, Inc. CONFIDENTIAL v

Appendix A - 1998 NINDS Consensus Guidelines.............................................................. A-1

Appendix B – Neuronetics Clinical Studies ..........................................................................B-1
B.1 Study 44-01101 .....................................................................................................B-2
B.2 Study 44-01102 .....................................................................................................B-7
B.3 Study 44-01103 .....................................................................................................B-9
Appendix C – Symbols ..........................................................................................................C-1
Appendix D – Abbreviations, Terms, and Definitions ......................................................... D-1
Appendix E – Treatment Graph Interpretation ......................................................................E-1
Appendix F – Electromagnetic Compatibility ....................................................................... F-1
Neuronetics, Inc. CONFIDENTIAL vi

1. Introduction The NeuroStar TMS System (see Figure 1-1) is a computerized

electromechanical instrument that produces and delivers brief
duration rapidly alternating, or pulsed, magnetic fields to induce
electrical currents directed at localized regions of the cortex.
Figure 1-1. Neuronetics NeuroStar TMS System

The NeuroStar TMS System is a non-invasive tool for the stimulation
of cortical neurons and is intended for the treatment of major
depressive disorder (MDD).
The NeuroStar TMS System is used for patient treatment by
prescription only and must be operated by a licensed medical
professional. It can be used in both inpatient and outpatient settings
including physician’s offices and clinics, psychiatric hospitals, and
general medical/surgical hospitals with psychiatric units.
The NeuroStar TMS System is offered in the following
configurations:
• Mobile Console standalone configuration (Mobile Console,
therapy coil, head support unit, and treatment chair)
• Mobile Console standalone configuration with Practice Data
Management System (PDMS)
• Multiple Mobile Consoles/PDMS configuration to address the
needs of facilities with large patient populations.
Neuronetics, Inc. CONFIDENTIAL 1-1

1.1. Technical The mechanism by which the NeuroStar TMS System has its
Overview intended effect derives fundamentally from Faraday’s Law, which
asserts that a time-varying magnetic field produces an electrical
current in an adjacent conductive substance. In transcranial magnetic
stimulation, the conductive substance is the brain, in particular the
region of the cortex that lies beneath the NeuroStar TMS System
coil.
The electric current induced in this region of the cortex travels in a
path orthogonal to the direction of the alternating magnetic field with
the point of maximum field strength and greatest current located
directly beneath the center of the coil. The induced current is
tangential to the scalp at the cortical surface, and diminishes in
magnitude with increasing depth. In the targeted area of the motor
cortex, where field strength achieves the stimulation threshold,
neuronal depolarization occurs. The peak magnetic field strength
achieved with each pulse in the cortex is approximately 0.5 Tesla.
Activation of adjacent cortical neurons occurs predominantly by
trans-synaptic pathways. Human functional neuroimaging studies
have shown that indirect change in brain functional activity also
occurs at cortical sites distant from the direct area of magnetic
stimulation presumably due to the known extensive neural circuits
among cortical brain regions.
The resulting neuronal depolarization and changes in brain
functional activity achieved with TMS are associated with various
physiological changes in the brain that are associated with
symptomatic relief of depression.
Treatment should not exceed the recommended stimulation
parameters as listed in Appendix A – 1998 NINDS Consensus
Guidelines.
1.2 Indications The Neuronetics NeuroStar TMS System is indicated for the
treatment of major depressive disorder (MDD).
The efficacy of the NeuroStar TMS System for MDD was established
in a nine-week randomized, sham-controlled clinical trial in
outpatients who met DSM-IV diagnostic criteria for MDD.
A major depressive episode as defined in the DSM-IV implies a
prominent and relatively persistent (nearly every day for at least two
weeks) depressed or dysphoric mood that represents a change from
previous functioning, and includes at least five of the following nine
symptoms, one of which is either of the first two symptoms:
• Depressed mood
• Markedly diminished interest or pleasure in usual activities
• Significant change in weight and/or appetite

• Insomnia or hypersomnia
• Psychomotor agitation or retardation
• Increased fatigue or loss of energy
• Feelings of worthlessness or excessive or inappropriate guilt
• Slowed thinking or impaired concentration
• Recurrent thoughts of death or suicidal ideation or a suicide
attempt.
The maintenance of an acute clinical response to the NeuroStar TMS
System in patients with MDD was demonstrated in a 24-week
uncontrolled clinical trial.
For a description of the clinical trials and their results, see Appendix
B.
1.3 Contra- When used as directed, the NeuroStar TMS System is safe and
indications effective. Treatment with the NeuroStar TMS System of areas of the
human body other than the patient’s cranium (head and scalp) is
contraindicated.
The NeuroStar TMS System is contraindicated for use for some
patients, as identified in the sections below. These patients should not
be treated with the system or will need to take special precautions
before treatment with the NeuroStar TMS System. To ensure safe
treatment, all patients must be screened for contraindications.

Implanted The NeuroStar™ TMS System treatment coil produces very strong
Electronic Devices pulsed magnetic fields which can affect certain implanted devices
and/or Conductive or objects. The magnetic field strength diminishes quickly with
Objects increasing distance from the coil. At ~30cm from the face of the
treatment coil, the peak magnetic field is less than 5 Gauss which
is the recommended static magnetic field exclusion level for many
electronic devices.
Metallic Objects in or near the Head

The NeuroStar TMS System is contraindicated for use for patients
having conductive, ferromagnetic, or other magnetic-sensitive
metals in the head or within 30cm of the treatment coil. Failure to
follow this restriction could result in serious injury or death.
Implants Controlled by Physiological Signals
The NeuroStar TMS System is contraindicated for use for patients
who have an implanted device that is activated or controlled in any
way by physiologic signals, even if the device is located outside
the 30cm distance. This includes pacemakers, implantable
cardioverter defibrillators (ICD’s) and vagus nerve stimulators
(VNS). The device is also contraindicated for patients using
wearable cardioverter defibrillators (WCD) , even if the device is
removed, due to the potentially unstable cardiac condition of such
patients. Failure to follow this restriction could result in serious
injury or death.
Implants Not Controlled by Physiological Signals
Patients may have other implanted devices or metallic objects
located in areas outside the 30cm distance from the coil during
TMS Therapy if such devices are not controlled by physiologic
signals. Examples include: sutures and implanted insulin pumps.
However, great care must be taken by the NeuroStar TMS System
operator to ensure that the treatment coil is never placed within
30cm of these implants, otherwise serious injury could result.
Wearable or Removable Devices
If patients have removable devices or objects that may be affected
by the magnetic field, the device(s) should be removed from the
patient area before treatment (e.g. earrings, hearing aids,
eyeglasses, cell phones, MP3 players, etc.) to prevent possible
injury or damage to the device. This also includes wearable
monitors and bone growth stimulators.
Metallic Object and Implant Checklist
Prior to treatment, each patient should be checked against the
items listed in Table 1-1, which summarizes compatibility
requirements for devices and conductive objects in the vicinity of

the NeuroStar™ TMS System treatment coil. This list is for

guidance in screening a patient for magnetic field compatibility; it
is non-inclusive, so prudent judgment must be applied for cases
not listed including contacting the device manufacturer if
compatibility is uncertain.
The items in Table 1-1 MUST be reviewed for each patient prior
to treatment with the NeuroStar™ TMS System. The colors in the
table have the following meanings:
• Red indicates contraindication.
• Yellow indicates that the treatment coil must be kept at a
safe distance (i.e. >30cm) from the device or object.
• Blue indicates devices that should be removed from the
patient area.

Table 1-1. Partial List of Devices and Objects that may be affected by the NeuroStar™ Magnetic
Field

1.4 Warnings To ensure the safe operation of the NeuroStar TMS System, you
must consider the following warnings before proceeding to
treatment.
Risk of Seizure No seizures have been reported with the use of the NeuroStar
TMS System in over 6000 patient treatments. However, caution
should be used when the NeuroStar TMS System is used in
patients who have a history of, or potential alteration in seizure
threshold. Be alert for signs of an imminent seizure and terminate
the treatment session if those signs appear. If a seizure threshold
altering medication was taken, the motor threshold determination
should be repeated prior to the next treatment session.
Patients with risk of seizure include those with:
• History of seizure or epilepsy,
• History of stroke, head injury, severe headaches, or
unexplained seizures,
• Presence of other neurologic disease that may be associated
with an altered seizure threshold, or
• Concurrent medication use as such as tricyclic antidepressants,
neuroleptic agents or other drugs that lower the seizure
threshold.
Worsening Patients with MDD may experience worsening of their depression

Depression or and/or the emergence of suicidal ideation and behavior
Suicidality (suicidality) or unusual changes in behavior, whether or not they
are being treated with an antidepressant, and this risk may persist
until significant remission of symptoms occurs. Patients
undergoing treatment for MDD should be observed closely for
clinical worsening and suicidality. If worsening of symptoms
continues, consideration should be given to changing the
therapeutic regimen, including possible discontinuation of
treatment with the NeuroStar TMS System.

Effects on Medical The NeuroStar TMS System should be used only as directed and
Devices should not be placed on or near other body locations due to its
Containing possible effects on devices implanted or located in those areas and
Electronics or that may be affected by the magnetic field. Effects of the
Ferromagnetic magnetic field may include the movement, heating, or dysfunction
of objects and devices that contain ferromagnetic materials (see
Material
1.3 Contraindications).
The NeuroStar™ treatment coil must be kept more than 30cm
from all electronic devices to prevent malfunction or damage to
the device. Additionally, certain implanted electronic medical
devices that process physiological signals, such as pacemakers,
may be more sensitive to the TMS magnetic field and could
malfunction resulting in patient injury or death. Patients,
physicians and others implanted with such devices should not be
treated or in the vicinity of the NeuroStar™ treatment coil when
it is pulsing.
1.5 Clinical This section lists information pertaining to the safe operation of
Precautions the NeuroStar TMS System.
Treatment In order to reduce the potential risk of seizure, observe the
Parameters published 1998 National Institute of Neurological Disorders and
Stroke (NINDS) Workshop report guidelines (Appendix A in this
manual). Treatment outside of these guidelines is not
recommended.
Hearing Protection The patient must always wear earplugs or similar hearing
protection devices with a rating of 30db of noise reduction when
being treated with the NeuroStar TMS System. When used with
appropriate hearing protection, the NeuroStar TMS System has
had no demonstrated effect on hearing or auditory threshold.
Hearing protection is also advised for the clinical operator if he or
she is frequently located within 6 feet (2 meters) of the coil for an
extended period during patient treatment.
Long-Term Effects Treatment with the NeuroStar TMS System was safely tolerated in
patients for periods up to 12 continuous weeks, and no negative
effects of treatment were reported during a 24-week follow-up
observation period. Experimental and observational evidence
indicates that exposure to the magnetic fields produced by the
NeuroStar TMS coil does not present any significant risk of
causing acute or long-term adverse effects.

1.6 Procedure This section lists the warnings and precautions associated with the
Warnings operation of the NeuroStar TMS system.
and
Cautions
Risk of explosion. Do NOT use the NeuroStar TMS System in the
Danger! presence of a flammable anesthetic mixture with air or with
oxygen or nitrous oxide.
Risk of electrical shock. Do NOT use the NeuroStar TMS System

Danger! in or near water or other liquids, or place liquids on or near the
mobile console or any of the cables or coil.
Risk of electrical shock. Do NOT open the panels of the

Danger! NeuroStar TMS System mobile console. There are no user-
serviceable parts in the system. If the system malfunctions, call
Neuronetics for assistance at (610) 640-4202.
Risk of electrical shock. Always turn the coil power switch to

Danger! “STANDBY” before you attempt to remove or connect a coil
cable to the mobile console.
Do NOT place the NeuroStar TMS System near other medical

equipment during operation. Malfunction of the other equipment
could result in injury or death.
Do NOT allow unsupervised children near an operating NeuroStar

TMS System. Serious injury could result.
A 20-minute interval between patient treatment sessions is

required to guarantee that the coil operates within temperature
specifications. If the therapy coil becomes uncomfortably warm
to the touch, immediately discontinue use of the stimulator.
Failure to observe the 20-minute interval between treatment
sessions could result in coil overheating and patient burns.
Discontinue treatment with the NeuroStar TMS System for any

patient who has a continued significant adverse reaction or
discomfort during or immediately after use. (Temporary mild
discomfort at the site of stimulation is normal during and/or
shortly after treatment.)
Operate the NeuroStar TMS System only with parts and
components provided and/or recommended by Neuronetics, Inc.
The performance of the NeuroStar TMS System cannot be
guaranteed if other parts or components are used.
Do not place computer discs, audio recording tapes, credit cards,

hotel room keys, or electronic automotive ignition keys on or near

the coil while operating. The NeuroStar TMS System produces

time varying magnetic fields that may affect the integrity of data
stored on these types of magnetic media if placed near an
operating coil.
Do not use the NeuroStar TMS System on patients who cannot

communicate levels of comfort or discomfort with the selected
treatment settings.
Operation of the NeuroStar TMS System requires special

precautions regarding electromagnetic compatibility (EMC) and
needs to be installed and put into service according to the
following EMC information:
• Portable and mobile radio frequency communications
equipment can affect the operation of the NeuroStar TMS
System.
• Use of a power cord other than the one provided with
may result in increased emissions or decreased EMC
immunity of the NeuroStar TMS System.
• Do not use the NeuroStar TMS System adjacent to or
stacked with other equipment. If adjacent or stacked use
is necessary, you must observe the NeuroStar TMS
System to verify that it is operating normally.
For more information on the NeuroStar TMS System’s
electromagnetic compatibility, see Appendix F.
1.7 Emergency If you should encounter a patient emergency situation that requires
Procedures immediate cessation of treatment, take the following steps
immediately:
1. Stop the treatment.
2. Press the brake release button on the coil and pull the coil
away from the patient.
3. Manage the patient’s condition and/or call for help.
In the event of an emergency building evacuation during a
treatment session, press the PAUSE button on the screen then
press the brake release button on the coil and move the coil away
from the patient. Assist the patient in getting up from the
treatment chair.

1.8 Special • The safety of TMS during pregnancy has not been established.
Patient Therefore, women of childbearing age should be questioned
Populations regarding the possibility of pregnancy prior to receiving
treatment.
• The safety of the use of the NeuroStar TMS System in anyone
younger than 18 years of age or older than 70 years of age has
not been established.
1.9 Adverse There were no deaths or seizures reported in Neuronetics studies 44-
Experiences 01101, 44-01102, or 44-01103.
The most frequently reported events were headache and application
site pain. Headache was equally represented in both active and sham
TMS groups. Application site pain was more frequently represented
in the active TMS group. Both headache and application site pain
lessened with time over the TMS treatment course.
There was no evidence of clinically significant cognitive function

Additional Clinical testing change at either 4 weeks or 6 weeks associated with acute
Safety Testing: treatment with the Neuronetics NeuroStar TMS System
Cognitive There was no evidence of clinically significant auditory threshold
Function and change at either 4 weeks or 6 weeks associated with acute treatment
Auditory with the Neuronetics NeuroStar TMS System (with use of earplugs
Threshold during TMS treatment).
The following table presents a summary of MedDRA preferred term

adverse events occurring with an incidence on active TMS of > 2%
and greater than the incidence on sham TMS.
Body System Sham (N=158) Active (N=165)

Preferred Term N (%) N (%)
Ear and labyrinth disorders

- Ear pain 1 (0.6) 4 (2.4)
- Tinnitus 2 (1.3) 7 (4.2)
Eye disorders
- Eye pain 3 (1.9) 10 (6.1)
- Lacrimation increased 1 (0.6) 7 (4.2)
- Visual disturbance 2 (1.3) 4 (2.4)
Gastrointestinal disorders
- Diarrhea 6 (3.8) 8 (4.8)
- Nausea 10 (6.3) 17 (10.3)


- Toothache 1 (0.6) 12 (7.3)
- Vomiting 3 (1.9) 7 (4.2)
General disorders and site

administration conditions
- Application site
discomfort 2 (1.3) 18 (10.9)
- Application site pain 6 (3.8) 59 (35.8)
- Facial pain 5 (3.2) 11 (6.7)
- Pain 3 (1.9) 7 (4.2)
- Pyrexia 1 (0.6) 4 (2.4)
Injury, poisoning and
procedural complications
- - Overdose (Extra pulses 0 4 (2.4)
due to procedural error)
Musculoskeletal and
connective tissue disorders
- Arthralgia 5 (3.2) 10 (6.1)
- Muscle twitching 5 (3.2) 34 (20.6)
- Musculoskeletal 4 (2.5) 5 (3.0)
stiffness
4 (2.5) 8 (4.8)
- Neck pain
Nervous system disorders

- Dyskinesia 2 (1.3) 5 (3.0)
- Headache 87 (55.1) 96 (58.2)
- Hypoaesthesia 2 (1.3) 5 (3.0)
- Paraesthesia 4 (2.5) 6 (3.6)
- Tension headache 2 (1.3) 4 (2.4)
Psychiatric disorders
- Agitation 3 (1.9) 4 (2.4)
- Anxiety 18 (11.4) 19 (11.5)
Reproductive system and

breast disorders
- Dysmenorrhoea 2 (1.3) 5 (3.0)
Respiratory, thoracic and

mediastinal disorders


- Cough 2 (1.3) 4 (2.4)
- Dyspnoea 1 (0.6) 6 (3.6)
Skin and subcutaneous tissue

disorders
- Pain of skin 1 (0.6) 14 (8.5)
1.10 Minimal The NeuroStar TMS System is used by prescription only under the
Operator supervision of a licensed physician. The system can only be
operated by licensed medical professionals who have medical
Training training and who assist as part of the staff and who are operating
under the direction of a physician. The user of the NeuroStar TMS
System must be trained on its operation, and must have knowledge
of the operational environment.
NeuroStar TMS System operators must complete Neuronetics-
provided training before using the system.
1.11 General The NeuroStar TMS System consists of the following major
System components.
Description
Equipment and • Mobile Console (includes processor module, power
Software module, mast, gantry, halo, and display arm)
• System Software 1.0
• Therapy coil
• Head Support Unit (includes coil positioning guide)
• Treatment Chair
• Cushion Set (to enhance the comfort and positioning of the
patient in the required posture for the duration of the
treatment session)
Options • Practice Data Management System (PDMS) 1.0
• PDMS Package (includes PDMS 1.0, a configured
computer, and the wireless interface)
• Positioning pad set

Supplies (for each • Head cushion liner

treatment session) • Head side pad liner
• Earplugs
• SenStar™
1.12 Connection
to Other Additional equipment connected to medical
electrical equipment must comply with the
Equipment
respective IEC or ISO standards (e.g. IEC 60950
for data processing equipment). Furthermore, all
configurations shall comply with the requirements
for medical electrical systems (IEC 60601-1-1 or
clause 16 of the 3Ed. of IEC 60601-1,
respectively). Anybody connecting additional
equipment to medical electrical equipment
configures a medical system and is therefore
responsible that the system complies with the
requirements for medical electrical systems. Local
laws may take priority over the above mentioned
requirements. If in doubt, consult your local
representative or the technical service department.
1.13 HIPAA The NeuroStar TMS System fully complies with Federal HIPAA
Compliance regulations. Patient data is securely stored. Access to the system
is controlled by user name/password combinations. Passwords
entry is unreadable on the display screen. Patient identification
information is kept confidential and is accessible only to
authorized system users. The system maintains patient records
through unique identifiers.
The optional PDMS operates on a separate system, and the data
that is transferred is protected by a wireless encryption program to
protect the confidentiality of patient data.

NeuroStar TMS System User Manual 52-40001-000 DRAFT 005
2. NeuroStar This section provides a guide to the individual NeuroStar TMS

System components and controls and explains the basic terminology
TMS used in this manual.
System
Controls
2.1 NeuroStar The NeuroStar TMS System consists of a combination of hardware,
TMS software, and consumable supplies. It is delivered in either a basic
configuration or with optional features. Operation of the system
System requires the use of disposable supplies.
Overview
Major hardware components are illustrated in Figure 2-1.
2.2 Standard The basic configuration includes the following components:

Configuration • Mobile Console – An enclosed module that forms NeuroStar
TMS System’s wheeled base and integrates various
subsystems into a single package. It houses or supports the
processor module, the power module, the gantry, the display
arm, the mast, and the display.
• System Software 1.0 – A proprietary application that
provides the NeuroStar TMS System graphical user interface
(GUI) and incorporates work flow management to guide the
system user through a TMS procedure, and also supervises
and controls various subsystems.
• Coil – An enclosed electromagnet that is mounted to the coil
gantry which supports its weight as it is placed against the
patient’s head. The coil generates and applies a pulsed
magnetic field to tissue immediately beneath the coil in
response to commands from the processor and power
modules.
• Treatment Chair – An operator controlled, adjustable chair
that positions the patient comfortably at a desirable height
and angle for TMS treatment and provides lumbar support. It
includes a separate attachment for the chair that provides
adjustable head support and includes a guidance apparatus to
aid in positioning the coil on the patient’s head.
• Head Support Unit – An electro-mechanical device that
consists of several parts that are designed to provide
maximum patient comfort and reliable coil position
measurement of the patient’s MT location and TMS treatment
location.

Figure 2-1. . NeuroStar TMS System Main Hardware Component

Mobile Console The Mobile Console is the central workstation for a TMS procedure
using the NeuroStar TMS System and is the main control center for
all NeuroStar TMS System subsystems. The Mobile Console houses
the Power Module, the Processor Module, the Gantry Assembly,
Mast, and the Display Arm Assembly. The Mobile Console has an
enclosed frame with rear doors for service. This unit provides
interfaces for input power, coil power, and networking. Containment
in this enclosure keeps these connections out of the reach of the user
and out of the patient’s view.
As illustrated in Figure 2-2, the Mobile Console is mounted on medical
grade locking wheels with sufficient radius to clear elevator
thresholds and other small irregularities in floor surfaces. It also has
a handle that the user grips when positioning for treatment or moving
it to a new location. The rear of the mobile console includes a
drawer for storage.
Figure 2-2. NeuroStar TMS System Mobile Console (Side View)
Display As illustrated in Figure 2-3, the display has touch-activated images of

alphanumeric keys and buttons for user interaction with the system,
and displays graphic representations of system activity, messages,
and alarms.

Figure 2-3. Display with Touch Screen

The display is capable of presenting graphics, text displays, and touch
controls and provides graphics system resolution of 1024 x 768 with a
15” display. It is readable from 10 feet away in ambient light up to
6,000 foot candles.
The position of the display is adjustable for comfortable viewing by
the user during various stages of the workflow. It swings both sides
to accommodate both left and right side patient treatments (right side
use is for research use only). The display’s mounting is rigid enough
such that during normal touch screen operation, the display does not
move.
The display has a viewing angle of at least 150° from side to side. It
has two degrees of freedom:
• Rotation around the vertical axis (320°)
• Rotation about the horizontal axis (+ 30° from vertical).
The display presents graphical user interface screens as described in
Section 4 of this user manual.

The green LED on the lower corner of the display

indicates that the display is getting power. If you shut
down the system, as described in Section 4.4 of this
manual, but leave the power switch in the ON
position, the green LED will flash on and off at three
second intervals until the power switch is moved to
the OFF position.
Gantry The gantry consists of a lateral translation table within the Mobile
Console, a vertical mast, a balance arm, and a halo assembly that
connects to the coil as shown in Figure 2-4.
Figure 2-4. Gantry: Showing the Coil, Halo, Mast, Display Arm
The gantry supports the weight of the coil and allows free movement
for easy placement on the patient’s head. It incorporates electro-
mechanical brakes that automatically lock four degrees of motion
when the push-button switch on the coil is released, or when
commanded under software control. The brakes are designed to lock
upon loss of power or when the Mobile Console is not powered.
There are three degrees of freedom in the mechanism that
immediately connects to the coil (the “wrist”) of the support arm.
There is a manual brake to stop motion of the halo ring and a manual
brake to adjust coil axial rotation resistance. To facilitate exchanging
the coil for service or for research applications (e.g., swapping active
and sham coils), the user can mechanically disconnect the coil from

the halo using the release pin in the Halo Clamp Housing. (See
Section 5.4. in this manual.)
The display arm moves separately from the gantry along a horizontal
plane, enabling the user to adjust the position of the display.
Coil The coil generates a magnetic field that penetrates the skull and
reaches the patient’s cortex when the coil is placed against the
patient’s head. This pulsed field is controlled by the NeuroStar TMS
System power module and system software in response to user
settings.
During treatment, a single-use SenStar™ is attached to the face of the
coil and provides the contact surface with the patient’s head. The coil
mechanically attaches to the halo, as illustrated in Figure 2-5. Coil
buttons for brake release, pulsing, and MT level adjustment are
located just above the coil handle. For convenience a second brake
release button is located under the handle.
Figure 2-5. Coil Parts

During coil positioning, the user typically grasps the handle with
one hand and the coil top with the other before pressing one of the
brake release buttons. Holding the coil in this manner gives the
user more flexibility and control over placement while the brakes
are released.
System Software The NeuroStar TMS System Software 1.0 controls all internal
1.0 system functions, monitors system status to ensure safe operation
and provides the user with a graphical means to manage the course
of TMS treatment. Three important user features of the system
software are:
• Graphical User Interface (GUI) – This is the user’s
primary, graphical touch screen interface with the system.
Interactive buttons, fields, and images are displayed that

enable the user to direct and interact with system functions,
such as entering data, starting and stopping treatment, and
running diagnostics.
• MT Assist® - This feature facilitates motor threshold
determination by calculating a predicted MT value based
on a series of observations of muscle twitches in response
to coil pulses, as reported by the user.
• Diagnostics – The embedded diagnostic software consists
of an automated set of instructions that test and verify the
operation of system components
Treatment Chair The treatment chair is an electromechanical device on which the
patient is seated during treatment with the NeuroStar TMS System.
The chair resembles the type of chair used in dental treatment
environments and is commercially available for use in other
environments. It was selected for use with the NeuroStar TMS
System because it meets the treatment regimen requirements for
comfort, safety, and efficacy.
The treatment chair includes a wired pushbutton control unit that
adjusts the chair height, the patient’s reclining position, and the
patient’s leg support. It also includes a substantial base for overall
stability and a built-in adjustable lumbar support cushion for
patient comfort. The seat tilt feature helps lift the patient’s seat to
avoid patient slouching. The chair is wide enough to
accommodate a range of patient sizes.
Head Support Unit The Head Support Unit consists of several parts that are designed
to provide maximum patient comfort and reliable coil position
measurement of the patient’s motor threshold (MT) location. The
individual parts are identified in Figure 2-6.

Figure 2-6. Head Support Unit with Patient Alignment Parts

• Head Support – An electro-mechanical attachment mounted
on the patient chair that provides comfortable support for the
patient’s head during treatment sessions. It can be set at
different heights, angles, and distances to accommodate a
range of patient positions in response to patient physical
characteristics. Specifically, it has degrees of freedom that
enable the user to adjust the head support in the anterior-
posterior as well as the inferior-superior directions for patient
comfort.
• Side Pad and Bracket – A moveable cushion that is
mounted on a bracket designed to be set up on either the left
or right side of the patient’s head. The user can move the
side pad toward or away from the side of the patient’s head
until a comfortable position has been established.
• Superior Oblique Angle (SOA) Guide - An angle indicator
located behind the head support cushion associated with a
pivot arm that supports the AP Guide. The pivot arm allows
the AP Guide to be rotated through a range of superior
oblique angles +/- 90° from the mid-sagittal position.
• Anterior/Posterior (AP) Guide - A straight flat scale that
aids the clinician in accurately positioning the coil. The AP
guide moves parallel to the patient’s AP axis and provides a
calibrated index of its position.
• Lateral Canthus (LC) Guide - A flat scale oriented in the
patient’s superior/inferior direction and located behind the
head support cushion. This scale is used to indicate a
reference position for aligning the patient’s head to the Head

Support Unit for repeatable positioning from session to

session.
• Coil Angle Indicator - A flat curved scale that is attached to
the end of the AP guide. It enables the user to record the
position of the coil up to 20° to the left or right of the center
location.
Cushion Set This is a set of cushions that can help enhance the comfort and
positioning of the patient in the required posture for the duration of
the treatment session.
2.3 Options The following options are available.
Practice Data The optional Practice Data Management System (PDMS) is a
Management software package that runs on an external PC with a wireless
System (PDMS) connection capability to one or more mobile consoles. This package
1.0 is useful for tracking and documenting patient treatments and
outcomes. It is also useful to users of multiple NeuroStar TMS
Systems who need a centralized management apparatus.
PDMS Package The optional PDMS package includes the PDMS 1.0 software and a
personal computer that is equipped with a wireless connection that
provides communication with one or more NeuroStar TMS System
mobile consoles.
2.4 Supplies Operating the NeuroStar TMS System requires the use of the
following supplies:
• SenStars™
• Head Cushion Liners
• Side Pads
• Side Pad Liners
• Earplugs.
Your system was delivered with a starter kit containing the following
quantities:
• SenStars™ (50)
• Head Cushion Liners (100)
• Side Pads (3)
• Side Pad Liners (50).

SenStar™ As illustrated in Figure 2-7 and Figure 2-8, the SenStar™ is a one-time
use disposable component that serves four primary purposes:
• It includes a contact sensing element that detects when the
coil is properly positioned against the patient’s head.
• It detects the level of the magnetic field being applied by the
coil.
• It reduces the magnetic field at the patient’s scalp (without
affecting the deeper therapeutic field in the cortex) to aid in
patient comfort during treatment.
• It provides a clean hygienic surface for each treatment
session.
Figure 2-7. SenStar™ - Patient Figure 2-8. SenStar™ - Coil

Contact Surface Contact Surface
Head Cushion The Head Cushion Liner is a thin, tissue-like disposable cover that is
Liner placed on the Head Cushion as a hygienic barrier for each patient
session.
Side Pad The head support system offers the patient further comfort through
the use of a side pad that could be set up both on left or right side of
the patient’s head. The side pad is a replaceable foam pad that is
mounted on the side pad bracket. During treatment, the side pad is
covered by a disposable side pad liner.
Side Pad Liner The side pad liner is a thin, tissue-like disposable cover that is placed
on the side pad as a hygiene barrier for each patient session.
Ear Plugs The ear plugs are commercial grade noise reduction supplies made of
malleable foam for custom fit in the ear canal. When properly
inserted, they can provide up to 30db noise reduction.

3 Daily This section provides steps for you to take at the beginning of each
Treatment day to prepare the treatment room for TMS sessions.
Room
Preparation
3.1 Completing At the start of each treatment day, complete the following
the checklist.
Checklist Action Checked
1. There are no cracks in or damage to the coil
housing, the gantry and mast covers, or to the
mobile console covers.
2. There is no visible damage to the power cable.
3. The power cable is plugged into the wall socket.
4. The coil cable is connected to the mobile
console.
5. When the power switch is turned to ON, you
can hear the mobile console internal fan
running.
6. The touch screen displays the system boot-up
process and the Welcome screen.
7. The system processor check, the power module
check, and the treatment coil check pass.
8. The touch screen responds when you touch the
CONTINUE button.
9. Pressing and holding the brake release button on
the coil enables you to move and reposition the
coil, gantry, and mast.
10. Releasing the brake release button on the coil
locks the coil, gantry, and mast in place.
If you encounter a problem with any item in this checklist, use the
troubleshooting table in section 5.4 of this manual to identify the cause
and possible remedy.

3.2 Preparing Prepare the equipment as follows:

the • Move the mobile console away from the back of the chair.
Treatment
• Position the coil up and out of the way and the display arm in
Room the park position.
• Position the side pad bracket in the vertical position.
• Position the SOA guide 90 degrees to patient’s right (park
position).
• Position the A/P guide all the way back (park position).
• Position the coil angle indicator at the 0 position.
• Remove the Coil Retainer from the AP Guide.
• Position the chair in its upright position with the leg support
in its vertical position and the chair at its lowest height.
• Position the head support in line with the back of the chair.
To prevent the system from overheating, do NOT

block the fan vent or position the fan vent against a
wall or other obstacle. Also, make sure that the
room temperature is lower than 86° F.
The mobile console power cord presents a tripping
hazard. Ensure that the power cord is safely out of
your working area and out of the patient’s path.
3.3 Attaching You must attach a new SenStar™ to the face of the coil for each
the patient session.
SenStar™ to
the Coil
The SenStar™ comes into direct contact with the

patient’s scalp. Handle the SenStar™ carefully.
Keep it away from contaminants or other
substances. If the patient reports skin irritation
where the SenStar™ contacts the patient’s scalp,
replace the SenStar™.
SenStars™ are one-time use, disposable supplies. A

SenStar™ is new until you have attached it to an
operating coil. After you have initiated an MT
location task or a treatment session, the SenStar™
cannot be reused. However, the same SenStar™
can be used for both MT location and treatment
when MT location and treatment are performed
during the same session. If you have inadvertently

installed a used SenStar™, the system prompts you

to install a new unused SenStar™ when you log into
the system.
1. Position the coil as illustrated in Figure 3-1.
Figure 3-1. Installing the SenStar™

2. Press the SenStar™ connector into the coil connector groove.
3. Press the SenStar™ shunt into the coil shunt groove.
3.4 Starting The steps in this section enable you to do the following:
Up and • Start the system
Logging • Log in as an authorized user.
• Run the pulse test to verify that the system is properly set up for
In
treatment.
To complete these steps, you must first properly install a

SenStar™, as described in Section 3.3 of this manual.

Step 1: Start 1. Move the ON/OFF switch on the back of the mobile console
the System. to the ON position.
2. When the Microsoft® Windows™ self-diagnostics routine
has finished, double-touch the NeuroStar TMS System icon
on the desktop. In response, the system automatically runs
the self-diagnostics application and displays the diagnostic
routine’s progress on the touch screen.
3. If all diagnostics tests pass, the power-on diagnostics screen
prominently displays the following message for 5 seconds:
All start-up tests passed. The system is functional. (See
Figure 3-2.)
When the self-diagnostics routine has finished, the

system activates the brake release button on the back
of the coil. Press the brake release button and move
the coil out of the way before attempting to wheel the
mobile console into the treatment position.

Figure 3-2. System Self-Test Screen
After 5 seconds, the system displays the user login screen. (If you touch the CONTINUE
button before 5 seconds have elapsed, the system advances you to the login screen.) The
User ID field displays the user ID of the previous user.
If any diagnostics test fails, the power-on diagnostics screen prominently displays the
Neuronetics System Help telephone number. Call that telephone number before
attempting to use the system.
Press and hold the brake release button on the coil and move the gantry up and out of the
way.
Release the coil brake release button.

Normally, you should do Steps #5 and #6 before

you shut the system down at the end of the day.
However, if this was not done by the last user, you
must do it.
Step 2: Log In. The NeuroStar TMS System provides two levels of user privileges:
• User, and
• Administrator.
Individuals who have administrator privileges have all the privileges
of a user plus the ability to add new users to the system. (See
section 5.1.)
1. Use the on-screen keyboard to enter your assigned user ID
and password and touch the LOGIN button on the screen as
illustrated in Figure 3-3.
Figure 3-3. Login Screen

2. When a valid user ID and password combination has been

entered, the system displays the SenStar™ Detection Screen
(Figure 3-4). If you have not attached a SenStar™, or if the
SenStar™ has already been used, the system prompts you to
attach a new SenStar™ and disables the TEST PULSE
button until you have done this.
Figure 3-4. SenStar™ Detection Screen
When a new SenStar™ has been detected, the system

enables the TEST PULSE button on the touch screen. If
there is no contact detected on the SenStar™, the system
generates an audible success tone.

Step 3: Run the Before using the system, you must perform the pulse test. In this test,
Pulse Test the system generates two pulse sets.
If the system fails to detect the levels of these pulses, it displays a
failure message and prevents you from performing treatments or MT
searches.
If the test is successful, the system enables the CONTINUE button.
Keep the coil away from the patient’s head during this
test!
1. Touch the TEST PULSE button on the touch screen. In
response, the system displays a progress screen, as illustrated in
Figure 3-5.
Figure 3-5. Test Pulse Progress Screen

You can also use the pulse button on the coil to

initiate the pulse test, as illustrated in Figure 3-6.
Figure 3-6. Coil Pulse Button

2. When the test is finished, the system displays the verification
screen, as illustrated in Figure 3-7.

Figure 3-7. Test Pulse Completion Screen
3. Touch the CONTINUE button to display the Select Patient

screen, as illustrated in Figure 3-8.
If the test fails, make sure that the SenStar™ is properly

mounted on the coil and retry the test. If after a few tries the
pulse test continues to fail, try a different SenStar™. If
failures continue with a different SenStar™, call Neuronetics
for service.

Figure 3-8. Select Patient Screen

4. At this point, you can either follow the steps for an initial visit
(Section 4.3) or for a return visit (Section 4.5).


•
•
•
•
•
•
•

















•
•

•
•
•



•
•
•
•
•








•
•
•
•




° °
° ° °










•
•
•
•
•
•
•
•






•
•
•

















5.10 Understanding This section contains technical and theoretical background

the Technical Design information for individuals who want a better understanding
of how the NeuroStar TMS System works.
Transcranial magnetic stimulation (TMS) is the non-invasive

5.10.1 Principles application of a localized pulsed magnetic field to the surface of the
of Operation head causing depolarization of neurons in the cerebral cortex and
connected regions of the brain. In simple terms, a TMS stimulator
consists of a power supply, a single large capacitor for energy
storage, a triggering component that allows the charge stored on the
capacitor to discharge, and an inductive coil that receives the stored
energy. (See Figure 5-1.)
Figure 5-1. Simplified Schematic of a Representative Transcranial

Magnetic Stimulator (Note: component values are not identical with
the NeuroStar System)
The current flowing in the coil produces a time-varying magnetic

field that can penetrate the brain. The magnetic permeability of
biological tissue is approximately that of a vacuum. Therefore,
human tissues have no noticeable effect on the magnetic field itself,
allowing for a very predictable field to penetrate the brain.
Once the magnetic field penetrates the brain, it induces an electrical
current in the brain as predicted by Faraday's Law of Magnetic
Induction. (In 1831, Michael Faraday demonstrated that electric
currents could be induced in a conducting medium by the
application of a time-varying magnetic field.)
The NeuroStar TMS System technology stimulates cortical neurons
(and connected sub-cortical tissues) by using a time-varying
magnetic field to induce an electrical potential that causes ion flow,
or eddy currents in the cortex. If oriented correctly relative to the
membrane of the axon of a neuron, this ion flow results in a brief
depolarization of the membrane, causing the neuron to fire.
Stimulating neurons in the cortex with this technique has been
shown to modulate neuronal excitability with effects that last
beyond the time of direct stimulation.

Multiple stimulations delivered over a short period of time are

called repetitive transcranial magnetic stimulation, or TMS. TMS
can facilitate or inhibit neuron excitability as a function of
stimulation frequency. In the case of frequencies greater than 1 Hz,
it has been shown that TMS will facilitate firing, or lower the firing
threshold of the stimulated neuron. It is hypothesized that this
durable modulation effect may have therapeutic properties for the
treatment of depression.
The total magnetic field exposure that a patient experiences over a
four-week course of therapy (3000 pulses per day) is about 12
seconds. The patient is exposed to a peak magnetic field strength of
approximately 0.5 Telsa.
The discrete regions of the brain that are directly affected by the
NeuroStar TMS System therapy are illustrated in Figure 5-2.
Figure 5-2. Brain Regions Relevant to TMS Therapy

5.10.2 Main Processor:

Technical Memory:
Specifica- Storage:
tions Input Power:
Input Frequencies:
Operating System:
Input Device:
Touch Screen Specification:
Touch Screen Display Size:
Coil Weight:
Footprint:
Gantry Length:
Display arm Length:
Mast Length:
Mobile Console Weight:
Chair Length:
Chair Height:
Chair Width:
Chair Weight:
Chair Back Range of Movement:
Chair Leg Range of Movement:
Interface Ports :
Electrical Switches:

PDMS System
Requirements
PDMS
Transceiver
Specifications

Field The following items are replaceable by the clinical user:

Replaceable • Head Support Unit
Units
• Head Cushion
• Coil
• Cushion Set
• PDMS Software
The following items are designed to be replaceable by Neuronetics Field
Service personnel:
• Power Module
• Processor Module
• Display
• Covers
• Cables
• NeuroStar TMS System Software
• Treatment Chair
• Wireless Transceiver
• Printer
Operating The NeuroStar TMS System was designed to operate optimally in a

Environment typical clinical office environment.
Transport and
Storage
Environment
FDA The NeuroStar TMS System is a class (TBD) medical device. It is an

Classification active medical device that has no measuring function and that is
noninvasive and designed for intermittent use.
Industry Classification Area Classification
Standard
Classification
(IEC 60601-1)
Type of Electric Shock Protection Class I Equipment
Degree of Electric Shock Protection Type BF

Industry Classification Area Classification

Standard
Classification
(IEC 60601-1)
Degree of Protection Against Harmful Ingress of Ordinary

Water Equipment
Safety in the Presence of Flammable Material Equipment is NOT

suitable for use in
the presence of a
flammable
anesthetic mixture
with air or with
oxygen or with
nitrous oxide.
Mode of Operation Continuous

Operation with
Short-Term
Loading
Electro- This equipment has been tested and been found to comply with the
magnetic requirements of EN60601-1, Medical Electrical Equipment Part 1:
Compatibility General Requirements for Safety, and Collateral Standard:
(EMC) Electromagnetic Compatibility – Requirements and Tests (EN60601-1-
2). These requirements are designed to provide reasonable protection
against harmful interference when the equipment is installed and
operated as specified by Neuronetics. (See Appendix F for details.)
• The NeuroStar TMS System generates, uses, and can radiate
electromagnetic energy if not installed and used in accordance with
the instructions in this manual.
• If it is determined that the NeuroStar TMS System is generating
interference with other equipment contact the Neuronetics Service
Department.
Waste Used head cushion liners and side pad liners may be mixed with regular
Disposal trash. Used SenStar™ Treatment Links should be disposed of in the
container provided by Neuronetics.
At the end of the NeuroStar TMS System’s useful life, call the
Neuronetics Service Department for disposal instructions.

6 This section provides instructions for maintaining the NeuroStar

TMS System.
Maintaining • Basic Maintenance
the System Section 6.1 provides instructions for changing system
configuration parameters
• System Alarms
Section 6.3 provides instructions for addressing system
alarms and alarm messages
• Diagnostics
Section 6.4 provides the possible display messages on the
touch screen
• Troubleshooting
Section 6.5 provides routine system observations and
suggested corrective actions.
The NeuroStar TMS System is designed to provide reliable service
in a convenient self-contained package. The instructions in this
section cover preventive maintenance steps and the most basic
diagnostic and troubleshooting steps.
The NeuroStar TMS System software has many self-checking
features and displays error messages in the unlikely event that it
encounters problems.
There are NO user-serviceable parts in the

NeuroStar TMS System mobile console. If you
encounter a problem that is not covered in this
section, call the Neuronetics service line. If you
suspect that a system malfunction has created a
hazardous condition, unplug the power cord
from the wall outlet and call the Neuronetics
Service Department for assistance.
6.1 Routine Maintenance
• With the power off and the system unplugged from the wall
Cleaning and
receptacle, use a damp cloth to wipe away dust or dirt on the
Disinfecting
mobile console, the power cable, the signal cable, the
therapy coil, and the coil halo, gantry, and mast.
• Clean the surface of the therapy coil by wiping it with a
damp sponge and/or by blotting with a clean cloth, using a
water-based cleaning product or mild soap and water.

• Do NOT use any type of solvent or lubricant on the

component parts.
• Do NOT use acetone to clean any part of the system.
• Do NOT attempt to sterilize any part of the system.
Do NOT use glass cleaner, cleanser, or any abrasive substance on
the touch screen.
User Routine • Ensure that the system is set for the proper local voltage
Maintenance level and that it has the proper power cable.
• Ensure that the power cable plug is intact and that you are
connecting the system only to a grounded wall receptacle.
• Ensure that the mobile console housing, the gantry covers,
and the display case are intact. If there are any cracked or
broken areas, call Neuronetics for service.
• Use a sponge or cloth to soak up any small spills on the
equipment. If the spill includes bodily fluids, observe all
biohazard precautions.
• If a large amount of liquid is spilled on the unit, turn off the
system, disconnect the power cable from the wall receptacle,
and call the Neuronetics Service Department for assistance.
6.2 Preventive Call the Neuronetics service department to schedule an annual
Maintenance inspection and preventive maintenance visit.
6.3 Adjusting The NeuroStar TMS System is equipped with several audible alarms
System Alarms that alert you to conditions that require your attention. If these
alarms are disturbing to the patient or distracting, you can silence
them. If you silence alarms, the system will still display the alarm
messages on the screen. Use the following steps to silence alarms.







•
•
•
•
•
•
•
•
•
•
•
•









•
•
•
•
•
•
•
•


•
•
•

•
•
•
•
•
•











Appendix A - 1998 NINDS Consensus Guidelines

Anytime the user sets the pulse parameters that exceed the 1998 NINDS Consensus
Guidelines, as specified in the table below, the system posts the “Parameters Exceed 1998
NINDS Consensus Guidelines” alarm.
The table below shows the 1998 NINDS Consensus Guidelines for maximum single train
durations, in seconds, depending on %MT and PPS:
Maximum Duration of Single Trains

(seconds)
PPS Intensity (% MT)
100 110 120 130 140 150 160 170 180 190 200 210 220
1 >1800 >1800 360 >50 >50 >50 >50 27 11 11 8 7 6
5 >10 >10 >10 >10 7.6 5.2 3.6 2.6 2.4 1.6 1.4 1.6 1.2
10 >5 >5 4.2 2.9 1.3 0.8 0.9 0.8 0.5 0.6 0.4 0.3 0.3
20 2.05 1.6 1.0 0.55 0.35 0.25 0.25 0.15 0.2 0.25 0.2 0.1 0.1
25 1.28 0.84 0.4 0.24 0.2 0.24 0.2 0.12 0.08 0.12 0.12 0.08 0.08
Note: Numbers preceded by > are the longest durations tested. No after discharge or spread of excitation has been encountered with
single trains of rTMS at these combinations of stimulus frequency and intensity.
Table 1 Source: Reprinted from Wassermann EM: "Risk and Safety of Repetitive Transcranial Magnetic Stimulation: Report and Suggested
Guidelines," from the International Workshop on the Safety of Repetitive Transcranial Magnetic Stimulation, June 5-7,
1996. Electroencephalography and Clinical Neurophysiology 108(1):1-16, 1998. Reprinted with permission.
Neuronetics, Inc. CONFIDENTIAL A-1

Appendix B – Neuronetics Clinical Studies

The clinical development program for the Neuronetics TMS System consisted of three
integrated clinical protocols as displayed in Figure B-1.
Figure B-1. Neuronetics’ Clinical Studies and Patient Allocation
In brief, the efficacy of the Neuronetics TMS System was established in adult outpatients in a
9-week, randomized, sham-controlled clinical trial, Study 44-01101.
Patients who failed to receive benefit from their randomized assignment in Study 44-01101
were eligible to enter a 9-week, open-label cross-over study with the Neuronetics TMS
System in Study 44-01102.
The maintenance of an acute clinical response to the Neuronetics TMS System in either
Study 44-01101 or Study 44-01102 was established in a 24 week, open-label continuation
clinical trial, Study 44-01103.
These studies show that transcranial magnetic stimulation (TMS) as delivered by the
NeuroStar™ System is an effective, safe and well-tolerated antidepressant for the treatment
for patients with major depressive disorder. The acute response to TMS treatment can be
effectively maintained in a clinically meaningful manner during a follow up period of up to
24 weeks
Neuronetics, Inc. CONFIDENTIAL B-1

B.1 Study 44-01101

Title: A Randomized, Parallel-Group, Sham-Controlled, Multicenter Study to Evaluate the
Efficacy and Safety of the Neuronetics Model 2100 CRS Repetitive Transcranial Magnetic
Stimulation (rTMS) System in Patients with Major Depression.
Patients: Outpatients ages 18 to 70, meeting DSM-IV criteria for MDD, single episode or
recurrent, with a current illness duration of 3 years or less and who had never previously been
treated with TMS, were enrolled in Study 44-01101. The clinical diagnosis was confirmed
by structured psychiatric interview. Patients were required to have a minimum symptom
severity as reflected by a total score of at least 20 on the 17-item Hamilton Depression Rating
Scale (HAMD17). In addition, patients were evaluated using the Antidepressant Treatment
History Form (ATHF) and shown to have failed to receive benefit from at least 1 but no more
than 4 adequate trials of an antidepressant in their current episode (ATHF Level 3 resistance
rating). Patients who had failed to receive benefit from an adequate trial of electroconvulsive
therapy at any point in their lifetime were excluded. Patients with psychiatric disorders other
than MDD were also excluded. All patients were free of psychotropic medications for at
least one week prior to and throughout the trial.
Design and Methods: A total of 325 patients were enrolled in Study 44-01101. This study
design was comprised of three phases: a one week, no-treatment and drug washout lead-in
phase, a six week acute treatment phase, and a 3 week taper phase. During the taper phase,
treatment with the Neuronetics TMS System was tapered, while the patient was
simultaneously tapered on to monotherapy with oral antidepressant medication. At any time
after at least 4 weeks of participation in the acute phase of Study 44-01101, patients could be
considered for enrollment in Study 44-01102 or 44-01103.
Patients were randomized to receive either active treatment or sham treatment.
Randomization assignment was established prior to the start of the study, and was
electronically recorded on sequentially assigned treatment cards that were used to control the
operation of the Neuronetics TMS System in a blinded manner. This blinding method
ensured identical appearance, placement and acoustic properties of the Neuronetics TMS
System for both active and sham treatments. Efficacy outcome was assessed by study
personnel not included in the treatment session itself as an additional means to ensure the
study blind.
Treatment sessions were conducted in sequential five day series for the 6 week acute
treatment phase. Six additional treatments were administered across the 3 week taper phase.
The maximum number of treatments in was 36. Treatment parameters were standardized for
each treatment session using a magnetic field intensity of 120% of the patient’s observed
motor threshold, at a repetition rate of ten magnetic pulses per second. Pulses were grouped
in 30 second cycles with a stimulation on-time of 4 seconds, and an off-time of 26 seconds.
A treatment session lasted for 37.5 minutes for a total number of 3000 magnetic pulses per
session. Motor threshold was determined weekly by visual observation of thumb or finger
movement using MT Assist®, which is a standardized mathematical algorithm that provides
an iterated estimate of the motor threshold. The treatment location was over the left
prefrontal cortex, determined by a standard convention of movement of the TMS coil 5 cm
anterior to the motor threshold location along a left superior oblique angle.
The primary efficacy outcome was difference between active treatment and sham treatment
using the total score of the Montgomery Asberg Depression Rating Scale (MADRS) at week
4 of the acute treatment phase. Secondary outcome measures included active versus sham

outcomes using the total score of the 24-item Hamilton Depression Rating Scale, and
categorical outcomes such as 50% response rates and remission rates using both the HAMD
and MADRS scores. Functional status and quality of life was measured using the Medical
Outcomes Study 36-Item Short Form, and the Quality of Life Enjoyment and Satisfaction
Questionnaire. Safety was assessed by adverse event reports, and by targeted safety
evaluation of air-conduction auditory threshold. Cognitive function was assessed with the
Mini Mental Status Examination, the Buschke Selective Reminding Test, and the
Autobiographical Memory Inventory-Short Form.
Efficacy Results: Efficacy results for Study 44-01101 are summarized in Table B-2.
Statistical significance at p<0.05 is shown highlighted.
Table B-2. A Priori-Defined Primary and Secondary Outcome Measures Observed in Study 44-
01101. P Values for Contrasts Between Active TMS and Sham TMS Group for Intent-to Treat Study
Population (All Analyses Conducted in LOCF Manner)
P value P Value
Primary Efficacy Outcome Measure
Week 4 Week 6
MADRS Total Score .057 .058
1
MADRS Total Score (baseline imbalance corrected) .038 .052
P value P Value
Secondary Efficacy Outcome Measures
Week 4 Week 6
HAMD 24 Total Score .012 .015
HAMD17 Total Score .006 .005
MADRS Responder Rate .045 .007
HAMD 24 Responder Rate .030 .042
HAMD17 Responder Rate .018 .015
SF-36 Item Questionnaire v1: Physical Functioning .299 .229
SF-36 Item Questionnaire v1: Role Physical Score .361 .221
SF-36 Item Questionnaire v1: Bodily Pain Score .520 .301
SF-36 Item Questionnaire v1: General Health Score .049 .047
SF-36 Item Questionnaire v1: Vitality Score .179 .081
SF-36 Item Questionnaire v1: Social Functioning Score .183 .386
SF-36 Item Questionnaire v1: Role Emotional Score .105 .044
SF-36 Item Questionnaire v1: Mental Health Score .006 .015
Q-LES-Q Total Score .124 .035
MADRS Remission Rate .633 .011
HAMD24 Remission Rate .644 .012
HAMD17 Remission Rate .705 .065
HAMD Anxiety/Somatization Factor Score .025 .023
HAMD Core Depression Factor Score .012 .008
HAMD Maier Factor Score .003 .003

P value P Value
Primary Efficacy Outcome Measure
Week 4 Week 6
HAMD Gibbons Factor Score .007 .006
HAMD Retardation Factor Score .007 .003
HAMD Sleep Factor Score .211 .109
IDS-SR Total Score .058 .053
Clinician Global Impressions-Severity (CGI-S) Total Score .009 .012
Patient Global Impression-Improvement (PGI-I) Total .181 .107
Score
1
Recomputed analysis using a baseline cut-off for MADRS total score of 20 (see Section 13.1, Study Report
44-01101, Appendix 19)
Efficacy Conclusions: TMS therapy delivered by the Neuronetics Model 2100 TMS System
is statistically significantly superior to sham treatment at 4 and 6 weeks for key physician-
rated depression measures (HAMD 17, HAMD24 and CGI-S) and for the MADRS total
score when corrected for a statistically significant baseline score imbalance between active
and sham groups.
Additionally, all three key depression measures (HAMD17, HAMD24 and MADRS) were
statistically superior to sham treatment at 4 and 6 weeks for the clinically-meaningful
categorical outcomes for >50% reduction in baseline score.
This data indicate that the TMS therapy delivered by the Neuronetics Model 2100 TMS
System is effective in the treatment of major depressive disorder.
Durability of Effect: At the conclusion of the acute treatment phase, all remaining patients
were entered into a continuation phase referred to at the post-treatment taper phase. During
this portion of the study, all patients began a scheduled taper of their open-label, active TMS
treatment across a 3-week schedule. At the same time, all patients were initiated on open-
label pharmacotherapy with a single antidepressant medication selected from a protocol-
defined list.
Categorical responder and remission rates for the primary disease-specific efficacy outcome
measures (the MADRS, the HAMD24 and the HAMD17) were collected for all patients
continuing into the post-treatment taper phase. These results showed that:
• The clinical effect of active TMS is sustained during transition to single-drug

antidepressant monotherapy. This indicates that patients may be appropriately
transitioned to clinically relevant continuation treatment without loss of clinical
benefit achieved in the acute treatment phase.
Safety Results: The safety of TMS treatment using the Neuronetics TMS System was
evaluated by the collection and evaluation of serious adverse events, spontaneous adverse
events, cognitive function testing, auditory threshold testing and suicidal ideation.
Table B-3 summarizes adverse events by MedDRA-preferred term that occurred at an
incidence of > 2% on active and were greater than the incidence on sham.

Table B-3. Summary of MedDRA Preferred Term Adverse Events Occurring with an Incidence
on Active TMS of > 2% and Greater Than the Incidence on Sham TMS
Sham Active
Body System
(N=158) (N=165)
(-) Preferred Term
N (%) N (%)
Ear and labyrinth disorders
- Ear pain 1 (0.6) 4 (2.4)
- Tinnitus 2 (1.3) 7 (4.2)
Eye disorders
- Eye pain 3 (1.9) 10 (6.1)
- Lacrimation increased 1 (0.6) 7 (4.2)
- Visual disturbance 2 (1.3) 4 (2.4)
Gastrointestinal disorders
- Diarrhoea 6 (3.8) 8 (4.8)
- Nausea 10 (6.3) 17 (10.3)
- Toothache 1 (0.6) 12 (7.3)
- Vomiting 3 (1.9) 7 (4.2)
General disorders and site administration conditions
- Application site discomfort 2 (1.3) 18 (10.9)
- Application site pain 6 (3.8) 59 (35.8)
- Facial pain 5 (3.2) 11 (6.7)
- Pain 3 (1.9) 7 (4.2)
- Pyrexia 1 (0.6) 4 (2.4)
Injury, poisoning and procedural complications
- Overdose* 0 4 (2.4)
Musculoskeletal and connective tissue disorders
- Arthralgia 5 (3.2) 10 (6.1)
- Muscle twitching 5 (3.2) 34 (20.6)
- Musculoskeletal stiffness 4 (2.5) 5 (3.0)
- Neck pain 4 (2.5) 8 (4.8)
Nervous system disorders
- Dyskinesia 2 (1.3) 5 (3.0)
- Headache 87 (55.1) 96 (58.2)
- Hypoaesthesia 2 (1.3) 5 (3.0)
- Paraesthesia 4 (2.5) 6 (3.6)
- Tension headache 2 (1.3) 4 (2.4)
Psychiatric disorders
- Agitation 3 (1.9) 4 (2.4)
- Anxiety 18 (11.4) 19 (11.5)
Reproductive system and breast disorders
- Dysmenorrhoea 2 (1.3) 5 (3.0)
Respiratory, thoracic and mediastinal disorders
- Cough 2 (1.3) 4 (2.4)
- Dyspnoea 1 (0.6) 6 (3.6)
Skin and subcutaneous tissue disorders
- Pain of skin 1 (0.6) 14 (8.5)
Notes: * Overdose refers to events associated with inadvertent smart card operator error
resulting in > 75 trains of active or sham TMS delivered to the patient on a
single calendar day. Per protocol procedure, all of these events were
considered as adverse events to be reported in the time frame and manner of
serious adverse events.

• There were no deaths or seizures reported in Study 44-01101.
• The most common adverse events experienced by patients were headache (58.2%
active TMS treatment vs. 55.1% sham TMS treatment) and application site pain
(35.8% active TMS treatment vs. 3.8% sham TMS treatment). Both headache and
application site pain lessened with time over the TMS treatment course, with
application site pain substantially diminished within one week of treatment
commencement.
• There was no evidence of clinically significant cognitive function testing change at

either 4 weeks or 6 weeks associated with acute treatment with the Neuronetics
TMS System
• There was no evidence of clinically significant auditory threshold change at either 4

weeks or 6 weeks associated with acute treatment with the Neuronetics TMS
System (with use of earplugs during TMS treatment).
• There was no evidence that active TMS treatment was associated with worsening of
suicidal ideation or emergent suicidal ideation during the acute treatment phase.
Overall Safety and Efficacy Conclusions: Study 44-01101 established that TMS therapy
delivered by the Neuronetics TMS System is statistically significantly superior to sham
treatment at 4 and 6 weeks for key physician-rated depression measures (HAMD 17,
HAMD24 and CGI-S) and for the MADRS total score when corrected for baseline
imbalance.
All three key depression measures (HAMD17, HAMD24 and MADRS) were statistically
superior to sham treatment at 4 and 6 week for the clinically-meaningful categorical
outcomes for >50% reduction in baseline score.
The safety was shown by the collection and evaluation of serious adverse events,
spontaneous adverse events, cognitive function testing, auditory threshold testing and suicidal
ideation.
The data indicates that TMS therapy delivered by the Neuronetics TMS System is safe and
effective in the treatment of major depressive disorder.

B.2 Study 44-01102

Title: A 9-week, Uncontrolled, Open-Label Study to Evaluate the Efficacy and Safety of the
Neuronetics Model 2100 Repetitive Transcranial Magnetic Stimulation (rTMS) System in the
Treatment of Patients with Major Depression Previously Non-Responsive to Active or Sham
rTMS Treatment.
Patients: See Study 44-01101.
Design and Methods: A total of 166 patients were enrolled in Study 44-01102. Patients
who participated in Study 44-01101 for at least 4 weeks of acute phase treatment and who
failed to receive benefit from their randomized treatment assignment in that study, and who
also showed less than a 25% decline in their HAMD17 total score at exit compared to their
baseline score, were eligible for enrollment into Study 44-01102. Treatment assignment
from Study 44-01101 was not unblinded at the time of enrollment into Study 44-01102.
Study 44-01102 was an open-label, uncontrolled clinical trial otherwise identical in design
and treatment sequence to Study 44-01101.
Efficacy Results: Efficacy results for Study 44-01102 are summarized below for clinician-
rated outcome measures as shown in Table B-4 . The table shows the mean change in total
efficacy assessment scores, and responder and remission rates for patients who were
randomized in Study 44-01101 to either active TMS or to sham TMS and were subsequently
treated with open-label TMS in Study 44-01102.
Table B-4. Open-Label TMS Study 44-01102: A Priori-Defined Outcome Measures
Week 4 Week 6 Week 4 Week 6

Study 101 Study 101 Study 101 Study 101
Efficacy Outcome Measures
Active Non- Active Non- Sham Non- Sham Non-
Responder Responder Responder Responder
MADRS Total Score Mean Change1 -10.5 -12.5 -11.9 -17.0
1
HAMD 24 Total Score Mean Change -9.0 -11.1 -11.0 -14.5
1
HAMD17 Total Score Mean Change -6.4 -8.2 -8.2 -10.8
2
MADRS Responder Rate (%) 20.5 26.0 25.0 42.4
HAMD 24 Responder Rate (%) 21.9 31.5 28.2 42.4
HAMD17 Responder Rate (%) 21.9 30.1 27.1 37.6
3
MADRS Remission Rate (%) 5.5 11.0 5.9 20.0
4
HAMD24 Remission Rate (%) 9.5 16.4 12.9 27.1
5
HAMD17 Remission Rate (%) 6.8 15.1 10.6 21.2
1
Change in total score mean change from baseline at entry to Study 44-01102
2
Responder is >50% change from baseline score at entry to Study 44-01102
3
MADRS Remission is defined as MADRS total score <10
4
HAMD24 Remission is defined as HAMD24 total score <11
5
Efficacy Conclusions: Patients with major depression who have failed to receive adequate
clinical benefit from medication therapy show a clinically meaningful response to open-label
treatment with the Neuronetics TMS System.

After failure to receive benefit from their randomized treatment assignment in study 44-
01101, patients previously assigned to sham TMS show a consistent and numerically superior
clinical benefit with open-label TMS treatment in comparison with patients previously
assigned to active TMS.
A clinically meaningful proportion of patients who failed to receive clinical benefit after at
least 4 weeks of active TMS, respond successfully to an extended duration of active
treatment with TMS.
Durability of Effect: As in Study 44-01101, at the conclusion of the acute treatment phase,
all remaining patients were entered into a continuation phase referred to at the post-treatment
taper phase where they began a scheduled taper of their open-label, active TMS treatment
across a 3-week schedule with initiation onto open-label pharmacotherapy. The results
showed:
• Patients previously allocated to sham TMS treatment in study 44-01101 consistently

showed a greater clinical benefit during this continuation period in Study 44-01102 as
compared to those patients previously allocated to active TMS treatment.
evaluated by the collection and evaluation of serious adverse events, spontaneous adverse
events, cognitive function testing, auditory threshold testing and emergent suicidal ideation.
• There were no deaths or seizures reported in this study
• Adverse events and their temporal relationship in study 44-01102 were similar to that
reported in study 44-01101.
• Application site pain was observed in both treatment groups, but the incidence was
greater in the patient group that had previously been allocated to sham TMS
treatment prior to entry into study 44-01102, suggesting that the prior exposure
assisted in accommodation to this effect.
• For both headache and application site pain, the greatest incidence was observed
during the first week of treatment with a substantial reduction in incidence after the
first week of treatment, consistent with a rapid accommodation to these commonly
experienced events. This accommodation effect was more pronounced for
application site pain.
• There was no evidence of clinically significant cognitive function testing change at

either 4 weeks or 6 weeks associated with acute treatment with the Neuronetics TMS
System
• There was no evidence of clinically significant auditory threshold change at either 4

weeks or 6 weeks associated with acute treatment with the Neuronetics TMS System.
• There was no evidence that active TMS treatment was associated with worsening of
suicidal ideation or emergent suicidal ideation during the acute treatment phase.

B.3 Study 44-01103

Title: A 6-month, Open-Label Maintenance Study of Patients with Major Depression
Previously Responsive to rTMS Treatment with the Neuronetics Model 2100 CRS Repetitive
Transcranial Magnetic Stimulation (rTMS) System.
Patients: See Study 44-01101
Design and Methods: At total of 136 patients were enrolled in Study 44-01103. This study
was an open-label, uncontrolled clinical trial providing 24 weeks of continuation oral
antidepressant monotherapy to patients who showed a 25% or greater improvement in their
HAMD17 total score at the end of participation in either Study 44-01101 or Study 44-01102,
compared to their baseline HAMD17 score in those studies.
During the course of Study 44-01103, patients were permitted to adjust their monotherapy
antidepressant medication schedule as clinically indicated, but were not permitted to switch
or combine antidepressant regimens. In the event that a patient’s clinical symptoms
deteriorated as determined by change in the Clinical Global Impressions – Severity of Illness
score, observed on at least two sequential study visits, then open-label TMS treatment was
reintroduced in conjunction with continuation pharmacotherapy, for up to 24 sessions across
six weeks. Treatment with the Neuronetics TMS System was discontinued if symptom
resolution occurred. Patients were discontinued from this study if they experienced a
recurrence of DSM-IV defined MDD or if they failed to receive benefit from a full course of
reintroduction of treatment with the Neuronetics TMS System. Efficacy and safety outcomes
were assessed using the same measurement instruments as in Study 44-01101.
Interim Efficacy Results: The data reported for Study 44-01103 are interim in nature at this
writing. These data demonstrate that the durability of the acute treatment response to active
TMS is maintained over the first four weeks of TMS-free treatment expressed in terms of the
incidence of illness relapse. Using the protocol-defined definition of discontinuation for all
cause during this time interval, the cumulative incidence of relapse is 2.3%.
An alternative definition was also applied in an exploratory manner over this same time
interval, based on a definition of change in HAMD24 score derived (a relapse definition
commonly used in the ECT literature). Based on this definition, the cumulative incidence of
relapse across the first 4 weeks of TMS-free treatment is 9.1%.
Efficacy results for patients who were responders in the active treatment group in Study 44-
01101 and continued directly into Study 44-01103 (Group 1) are summarized in Table 10.7
and show mean score change and remission rates for MADRS, HAMD 24 and HAMD 17
item scores.
Table 5. A Priori-Defined Outcome Measures for Group 11
Efficacy Outcome Measures Week 1 Week 2 Week 3 Week 4
MADRS Total Score Mean Change2 -20.1 -21.4 -20.3 -21.2
HAMD24 Total Score Mean Change2 -18.0 -19.0 -18.4 -19.6
HAMD17 Total Score Mean Change2 -14.0 -14.4 -13.9 -14.6
MADRS Remission Rate (%)3 50 59.1 52.7 45.5
HAMD24 Remission Rate (%)4 47.7 54.5 47.7 43.2
HAMD17 Remission Rate (%)5 50 56.8 43.2 43.2
1
Group 1 are patients who were responders in the active treatment group in Study 44-01101

2
Baseline is defined as baseline of Study 44-01101
3
MADRS Remission is defined as MADRS total score <10
4
5
Overall, 38.2% of all patients in study 44-01103 have experienced at least one cycle of TMS
reintroduction during the 6 month duration of the study. Most treatments occur subsequent to
the first month, with the median time to reintroduction ranging from 6.5 to 11 weeks after
enrollment in study 44-01103. These results suggest that symptomatic change sufficient to
require TMS reintroduction occurs in less than half of the patients entering study 44-01103
overall, and that the time to reintroduction is not immediate, but occurs after approximately
1-3 months.
Interim Efficacy Conclusions: In patients who have shown an acute response to active
treatment with the Neuronetics TMS System, the rate of protocol-defined relapse over a 4
week period of observation is 2.3% (9.1% using a literature-based alternative definition of
relapse derived from the HAMD24 total score).
The acute response to active TMS treatment can be effectively maintained in patients treated
with antidepressant medication monotherapy during a 4 week period of follow up after their
last TMS treatment, as shown by the pattern of symptom change over that period:
• The mean change from baseline score prior to treatment shows a large, stable, and
clinically meaningful reduction in total symptom burden over a 4 week period of
maintenance treatment
• A majority of patients maintain a criterion score of remission as measured by either

the MADRS, HAMD24 or the HAMD17 that is stable over a 4 week period of
maintenance treatment
Depending upon their treatment path prior to entry into study 44-01103, the percentage of
subjects who experienced symptomatic worsening and were provided with reintroduction of
active TMS treatment for at least one cycle observed at this interim report across 24 weeks
ranged from 33.3% to 47.8%.
evaluated by the collection and evaluation of serious adverse events and spontaneous adverse
events for this interim report.
• There were no deaths, seizures or suicides.
• Patients who showed an acute response to TMS treatment during either controlled or
open-label treatment with the Neuronetics TMS System show a pattern of adverse
events during 24 week maintenance treatment with antidepressants that is consistent
with the expected profile of adverse events with medication use and with the
expected profile of adverse events seen in Neuronetics’ studies 44-01101 and 44-
01102.
Overall Safety and Efficacy Conclusions: A majority of patients who experienced

symptomatic response to acute TMS treatment in study 44-01101 showed a clinically
meaningful and stable pattern of symptomatic response during 4 weeks of maintenance
antidepressant pharmacotherapy alone. Active TMS was safe and well tolerated when
administered in an adjunctive manner with antidepressant pharmacotherapy.


Appendix C – Symbols
Symbol Meaning
Attention: Consult Accompanying Documents
Off (Power: disconnection from the Mains)
On (Power connection to the Mains)
Type BF Equipment
Dangerous Voltage
AC Power Input
Quantity of Contents
For Single Use Only. Do Not Reuse.
Storage Temperature Range
Latex-Free
Electrostatic Sensitive Device
Reset
Neuronetics, Inc. CONFIDENTIAL C-1

Symbol Meaning
USB Port
Network Connection
Electromagnetic interference may occur in the vicinity of equipment.
Neuronetics, Inc. CONFIDENTIAL C-2

Appendix D – Abbreviations, Terms, and Definitions

Highlighted terms refer to the main NeuroStar TMS System components.
Term Meaning
Alignment Guide A mechanical system that the clinician uses to register a patient’s
anatomical landmarks to help identify the coordinates and replicate
the motor threshold and treatment positions on the patient’s head.
A/P Anterior/Posterior (used in locating the patient’s MT).
APB Abductor pollicis brevis, the muscle used in the so-called method of
limits using either observation of twitch in the right APB muscle
(thumb).
Brake “Release to lock” type device placed on the coil assembly to hold the
coil in place.
Coil Electromagnet that is connected to the mobile console and gantry and
placed against the side of the patient’s head for therapy delivery
during a treatment session.
Contact Sensing Sensor and software used to detect contact between the coil and the
patient’s head.
Cushion Set Set of cushions to help enhance the comfort and positioning of the
patient in the desired posture for the duration of the treatment.
Display Touch screen and LCD combination that provides the user interface
for the NeuroStar TMS system. This is also the main user input
device.
EMC Electromagnetic Compatibility
EMG Electro-myograph. An electronic measuring device that senses
neurologically evoked potential with electrodes placed on the skin in
the area of interest. EMG could be used to sense a thumb twitch
when performing motor threshold determination.
Field Sensing Capability of detecting the magnetic field strength of the coil during a
test pulse sequence.
FRU Field Replaceable Unit. The highest level of unit to which a
malfunctioning component is integrated
Gantry A retractable mechanical arm that helps to suspend the coil in space
for positioning on a patient’s head. It supports various degrees of
motion to navigate the coil in free space and to move to a desirable
location for determining MT and for delivering treatments. It
supports the weight of the coil while permitting easy placement with
the Alignment Guide.
Halo Adjustable mechanical device to which the coil is attached. It is used
to position the coil properly against the patient’s head, and it includes
a manual brake so the resistance can be adjusted by the operator.
Neuronetics, Inc. CONFIDENTIAL D-1

Term Meaning
Head Cushion Soft, pliable cushion on the Head Support that provides comfort for
the patient’s head.
Head Cushion A disposable, single-use, hygienic paper sheet that is applied to the
Liner Head Cushion.
Head Support Frame and cushion attached to the treatment chair to support the
Unit patient’s head during a treatment session and to assist in coil
positioning.
HIPAA Health Insurance Portability and Accountability Act, a Federal law
that covers healthcare-related data processing identifiers and
transactions, and that mandates security and privacy in data
processing and communication.
Interval The period of time between pulse trains (seconds).
Lumbar Cushion Part of the treatment chair that consists of an adjustable cushion that
supports the lumbar region of the patient’s back during treatment.
LSOA Left Superior Oblique Angle. The angle formed by tilting a mid-
sagittal plane around an A/P axis (used in locating the patient’s MT
Position).
Mast The vertical pole portion of the gantry.
MDD Major Depressive Disorder
MEP Motor Evoked Potential
Mobile Console System component that contains the system electronics and controls
and supports the gantry and display arm.
MT Motor Threshold.
MT Assist® A patented computer program that enables the NeuroStar TMS
System user to pinpoint a patient’s MT location and MT level.
MTL Motor Threshold Level. The minimum value of an electromagnetic
pulse output needed to stimulate a patient’s motor strip to cause a
thumb twitch.
NINDS National Institute for Neurological Disorders and Stroke
PC Personal Computer
PDMS Practice Data Management System, the optional NeuroStar TMS
System patient management and reporting software that runs on a
separate personal computer and communicates with the NeuroStar
TMS System mobile console through a wireless connection.
Power Module Hardware that contains the power supply, power storage, discharge
circuits, and the controlling logic.
Processor Hardware that contains the computer and boards that control the user
Module interface and that drive the NeuroStar TMS system.
Pulse Repetition Measurement that defines the number of magnetic pulses occurring in
Rate a second. The unit for this parameter is in Pulses Per Second (PPS)

Term Meaning
Pulse Test A preliminary NeuroStar TMS System test in which the system
generates pulses of 1.2 and 2.1 SMT units. The system takes a
reading for each set. If the system fails to generate these pulses, it
displays a failure message and prevents the user from performing
treatments or MT.
Pulse Train The group of NeuroStar TMS System electromagnetic pulses
occurring during treatment stimulation time.
Save MT MT Assist® software option that enables the user to store in the
system the MT level for a patient.
SenStar™ A single-use disposable integrated flexible circuit that must be
attached to the coil prior to treatment to facilitate contact sensing and
magnetic field detection and to decrease the magnetic field at the
scalp surface to enhance tolerability during treatment
SI Superior/Inferior
Side Pad Soft, pliable cushion that offers counter forces to the coil to hold the
head in the desired position.
Simple View MT Assist® program screen that lists the patient’s MT level, the MT
search pass number, and a progress bar for the current search. (See
also, Tabular view.)
SMT Standard Motor Threshold
SMT Unit The amount of voltage required to stimulate the neurons in a person’s
brain 2 cm below the scalp. A measurement unit used to specify a
stimulator output level.
Stimulation Time The length of a pulse train (seconds).
(“Stim Time”)
System Processor Hardware containing the main processor and other PC components.
Board
System Software The main software residing in the processor module and running on
the NeuroStar TMS System processor board.
Tabular View MT Assist® application screen that lists for each pass in table format
the MT level, the MT Assist® pass number, and a yes/no field for the
clinician to record the observation of the patient’s thumb twitch. (See
also, Simple view.)
Treatment Chair Patient treatment platform in the form of a chair that seats the patient
comfortably at a electro-mechanically adjustable heights and angles
(between 45° and 90°) for treatment and includes the head support.
Treatment Coil The active and fully functioning electromagnetic coil that is
connected to the mobile console and placed against patient’s scalp for
treatment delivery during a TMS session.

Term Meaning
TMS Transcranial Magnetic Stimulation, a method of using very short
pulses of magnetic energy to stimulate nerve cells in the brain. TMS
will be used synonymously with Repetitive Transcranial Magnetic
Stimulation, which refers to TMS with repetition rates greater than 1
pps.
Treatment Electronic record containing the details of the patient’s treatment
Record sessions.
USB Universal Serial Bus. Port used to connect external devices to the
NeuroStar TMS System hardware.

Appendix E – Treatment Graph Interpretation

The NeuroStar TMS System software displays the treatment graph on the screen during a
treatment session.
The treatment graph displayed for any operation has the following base characteristics:
• The X-axis represents time. There are three readable labels on the X-axis showing
time remaining in minutes and seconds. There is a label below the Y-axis showing
the total treatment time.
• The Y-axis represents the %MT with major labels on the Y-axis for 0%, 80%, 100%,
120%, and 140%.
• The trains on the treatment graph are represented by filled boxes. The number of
filled boxes on the graph is the number of trains called for in the treatment
parameters.
• The height of each box is scaled to represent the current machine output level setting
based on the %MT.
• The width of each box is scaled to represent the Stimulation Time.
• The spacing between each box is scaled to represent the Interval Time.
• The first filled box is placed on the Y-axis, representing the fact that once the
treatment begins, pulses occur immediately.
• There is a colorized contact sensor display history integrated in the treatment graph,
showing green when the contact sensor is good and red when the contact sensor is
poor.
• There is a vertical line indicator at the time there was a pause in treatment. The
indicator for manual pauses is a light red color and labeled with a “P”. The indicator
for an auto pause due to contact sensing off is a bright red and is labeled “AP.”
• There is a current time vertical line that increments every second. This vertical line is
a sweeping cursor.
Neuronetics, Inc. CONFIDENTIAL E-1

Appendix F – Electromagnetic Compatibility

Table F-1. Neuronetics Declaration: Electromagnetic Emissions
The NeuroStar TMS System is intended for use in the electromagnetic environment specified
below. The NeuroStar TMS System user should ensure that the equipment is used in such an
environment.
Emissions Test Compliance Electromagnetic Environment - Guidance
RF Emissions Group 2 The NeuroStar TMS System must emit
CISPR 11 electromagnetic energy in order to perform
its intended function. Nearby electronic
equipment may be affected.
RF Emissions Class A
CISPR 11
The NeuroStar TMS System is suitable for
Harmonic Emissions Not applicable use in all establishments other than domestic
IEC 61000-3-2 and those directly connected to the public
low-voltage power supply network that
Voltage Not applicable supplies buildings used for domestic
Fluctuations/Flicker purposes.
Emissions
IEC 61000-3-3
(EN 60601-1-2 Table 201)
Table F-2. Neuronetics Declaration – Electromagnetic Immunity

Guidance and Manufacturer’s Declaration – Electromagnetic Immunity
The NeuroStar TMS System is intended for use in the electromagnetic environment specified
below. The customer or user of the NeuroStar TMs System should assure that it is used in
such an environment.
Immunity IEC 60601 Compliance Electromagnetic Environment – Guidance
Test Test Level Level
Portable and mobile radio frequency
communications equipment should be no closer
to the NeuroStar TMS System, including
cables, than the recommended separation
distance calculated from the equation
applicable to the frequency of the transmitter.
Recommended Separation Distance

Conducted 3 VRMS 3V
RF IEC 150 kHz to
Neuronetics, Inc. CONFIDENTIAL F-1

Guidance and Manufacturer’s Declaration – Electromagnetic Immunity

61000-4-6 80 MHz
Conducted 3 VRMS 3V/m
RF IEC 80 MHz to
61000-4-3 80 MHz to 800 MHz
2.5 GHz
800 MHz to 2.5 GHz

where P is the maximum output power rating
of the transmitter in watts (W) according to the
transmitter manufacturer and d is the
recommended separation distance in meters
(m).
Field strengths from fixed RF transmitters, as
determined by an electromagnetic site survey,a
should be less than the compliance level in
each frequency range.b
Interference may occur in the vicinity of
equipment marked with the following symbol:
NOTE 1 At 80 MHz and 800 MHz, the higher frequency range applies.
NOTE 2 These guidelines may not apply in all situations. Electromagnetic propagation is
affected by absorption and reflection from structures, objects, and people.
a
Field strengths from fixed transmitters, such as base stations for radio (cellular/cordless)
telephones and land mobile radios, amateur radio, AM and FM radio broadcast, and TV
broadcast cannot be predicted theoretically with accuracy. To assess the electromagnetic
environment due to fixed RF transmitters, an electromagnetic site survey should be
considered. If the measured field strength in the location in which the NeuroStar TMS
System is used exceeds the applicable RF compliance level above, the NeuroStar TMs
System should be observed to verify normal operation. If abnormal performance is
observed, additional measures may be necessary, such as reorienting or relocating the
NeuroStar TMS System.
b
Over the frequency range of 150 kHz to 80 MHz, field strengths should be less than 3 V/m.
(EN 60601-1-2 Table 204)
Table F-3. Recommended Separation Distance between Portable and Mobile

RF Communications Equipment and the NeuroStar TMS System for Equipment
and Systems that are not Life-Supporting
Recommended Separation Distance between Portable and Mobile RF

Communications Equipment and the NeuroStar TMS System

The NeuroStar TMS System is intended for use in an electromagnetic environment in which
radiated RF disturbances are controlled. The customer or user of the NeuroStar TMs System
can help prevent electromagnetic interference by maintaining a minimum distance between
portable and mobile RF communications equipment (transmitters) and the NeuroStar TMs
System as recommended below, according to the maximum output power of the
communications equipment.
Rated Separation Distance According to Frequency of Transmitter (m)

Maximum
150 kHz to 80 MHz 80 MHz to 800 MHz 800 MHz to 2.5 GHz
Output
Power of
Transmitter
(W)
0.01 0.12 0.12 0.23
0.1 0.37 0.37 0.74
1 1.17 1.17 2.33
10 3.70 3.70 7.37
100 11.7 11.7 23.3
For transmitters rated at a maximum output power not listed above, the recommended
separation distance d in meters (m) can be estimated using the equation applicable to the
frequency of the transmitter, where P is the maximum output power rating of the transmitter in
watts (W) according to the transmitter manufacturer.
NOTE 1 At 80 MHz and 800 MHZ, the separation distance for the higher frequency range
applies.
NOTE 2 These guidelines may not apply in all situations. Electromagnetic propagation is
affected by absorption and reflection from structure, objects, and people.
(EN 60601-1-2 Table 206

NeuroStar TMS System™ User Manual
Neuronetics, Inc. CONFIDENTIAL iv

Neuronetics Neurostar Tms System™ User Manual: Confidential

Uploaded by

Copyright:

Available Formats

Neuronetics Neurostar Tms System™ User Manual: Confidential

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Neuronetics Neurostar Tms System™ User Manual: Confidential

Uploaded by

Copyright:

Available Formats

What is the intended use of the NeuroStar TMS System?

What is the intended use of the NeuroStar TMS System?

What are the user requirements and training needed to operate the NeuroStar TMS System?

What are the user requirements and training needed to operate the NeuroStar TMS System?

Neuronetics

52-40001-000 DRAFT 005a

Copyright ©2006 Neuronetics, Inc. All rights reserved.

Federal (U.S.A.) law restricts this device to sale by or on the order of a

User Requirements and Training

Intended Use and Indication

Patent and Trademark Information

The Neuronetics Web site address is http://www.neuronetics.com

To purchase supplies, accessories, or additional NeuroStar TMS Systems, call Neuronetics at

Copyright © 2006 Neuronetics, Inc.

Neuronetics, Inc. CONFIDENTIAL iii

How to Use This Manual

Neuronetics, Inc. CONFIDENTIAL iv

6 Maintaining the System .................................................................................................. 6-1

Neuronetics, Inc. CONFIDENTIAL v

Appendix A - 1998 NINDS Consensus Guidelines.............................................................. A-1

Neuronetics, Inc. CONFIDENTIAL vi

1. Introduction The NeuroStar TMS System (see Figure 1-1) is a computerized

Figure 1-1. Neuronetics NeuroStar TMS System

Neuronetics, Inc. CONFIDENTIAL 1-1

Neuronetics, Inc. CONFIDENTIAL 1-2

Neuronetics, Inc. CONFIDENTIAL 1-3

Metallic Objects in or near the Head

Neuronetics, Inc. CONFIDENTIAL 1-4

the NeuroStar™ TMS System treatment coil. This list is for

Neuronetics, Inc. CONFIDENTIAL 1-5

Neuronetics, Inc. CONFIDENTIAL 1-6

Worsening Patients with MDD may experience worsening of their depression

Neuronetics, Inc. CONFIDENTIAL 1-7

Neuronetics, Inc. CONFIDENTIAL 1-8

Risk of electrical shock. Do NOT use the NeuroStar TMS System

Risk of electrical shock. Do NOT open the panels of the

Risk of electrical shock. Always turn the coil power switch to

Do NOT place the NeuroStar TMS System near other medical

Do NOT allow unsupervised children near an operating NeuroStar

A 20-minute interval between patient treatment sessions is

Discontinue treatment with the NeuroStar TMS System for any

Do not place computer discs, audio recording tapes, credit cards,

Neuronetics, Inc. CONFIDENTIAL 1-9

the coil while operating. The NeuroStar TMS System produces

Do not use the NeuroStar TMS System on patients who cannot

Operation of the NeuroStar TMS System requires special

Neuronetics, Inc. CONFIDENTIAL 1-10

There was no evidence of clinically significant cognitive function

The following table presents a summary of MedDRA preferred term

Body System Sham (N=158) Active (N=165)

Ear and labyrinth disorders

Neuronetics, Inc. CONFIDENTIAL 1-11

Body System Sham (N=158) Active (N=165)

General disorders and site

Nervous system disorders

Reproductive system and

Respiratory, thoracic and

Neuronetics, Inc. CONFIDENTIAL 1-12

Body System Sham (N=158) Active (N=165)